| 1397 |
National Cancer Institute |
Html |
en |
Lymphedema (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of lymphedema, a condition in which lymph fluid builds up in tissues and causes swelling. |
| cancer treatment | 0.423589 |
| PDQ cancer information | 0.483377 |
| lymph flow | 0.481362 |
| leg | 0.408261 |
| left lymph duct | 0.48735 |
| white blood cells | 0.398624 |
| secondary lymphedema | 0.507085 |
| clinical trials | 0.422847 |
| cancer information summary | 0.440651 |
| clinical trial | 0.38593 |
| tiny lymph vessels | 0.509598 |
| breast cancer patients | 0.459436 |
| sentinel lymph node | 0.518746 |
| certified lymphedema therapists | 0.498842 |
| breast cancer survivors | 0.394173 |
| upper-body exercise | 0.39564 |
| NCI PDQ cancer | 0.395621 |
| Untreated lymphedema | 0.491735 |
| lymph nodes | 0.686068 |
| swollen area | 0.380684 |
| radiation therapy | 0.378654 |
| treatment | 0.447311 |
| Lymphedema section | 0.47523 |
| lymphedema sleeves | 0.47753 |
| severe lymphedema | 0.470942 |
|
| skin | 0.4219 |
| Cancer Information Service | 0.379239 |
| Primary lymphedema | 0.49612 |
| lymph | 0.792134 |
| body tissues | 0.403337 |
| larger lymph vessels | 0.508148 |
| Stage III lymphedema | 0.489621 |
| National Cancer Institute | 0.439823 |
| arm | 0.413813 |
| lymphedema therapist | 0.534874 |
| Palliative Care Editorial | 0.381473 |
| lymph vessels | 0.714976 |
| limb | 0.427251 |
| lymphedema | 0.932301 |
| certified lymphedema therapist | 0.527418 |
| breast cancer | 0.483638 |
| Care Editorial Board | 0.382648 |
| pressure garment | 0.387805 |
| lymphedema increases | 0.491902 |
| swollen limb | 0.388807 |
| lymph fluid | 0.457795 |
| cancer information summaries | 0.378678 |
| comprehensive cancer information | 0.377712 |
| cancer | 0.547119 |
|
CLICK HERE |
| 1548 |
National Cancer Institute |
Html |
en |
Breast Cancer Screening (PDQ®)–Patient Version |
Mammogram, clinical breast exam (CBE), and MRI (magnetic resonance imaging) tests are used to screen for breast cancer. Learn about this and other tests that have been studied to detect or screen for breast cancer in this expert-reviewed summary. |
| cancer screening methods | 0.42533 |
| fast-growing breast cancer | 0.440825 |
| ongoing clinical trials | 0.389452 |
| following PDQ summaries | 0.382952 |
| PDQ cancer information | 0.474492 |
| following PDQ summary | 0.39258 |
| breast fluid | 0.391775 |
| common screening test | 0.39988 |
| routine breast cancer | 0.436027 |
| clinical trials | 0.527662 |
| cancer information summary | 0.430839 |
| breast tissue sampling | 0.438767 |
| breast cancer prevention | 0.479726 |
| test results | 0.400913 |
| test | 0.410305 |
| Yearly MRI screening | 0.382239 |
| NCI PDQ cancer | 0.406053 |
| women | 0.476763 |
| PDQ Screening | 0.392324 |
| stage breast cancer | 0.437499 |
| screening tests | 0.377685 |
| breast cancer diagnosis | 0.443317 |
| clinical breast exams | 0.420114 |
| regular breast | 0.389266 |
| Cancer Information Service | 0.377203 |
|
| breast cancers | 0.414043 |
| denser breast tissue | 0.419753 |
| breast duct | 0.396464 |
| breast tissue | 0.495937 |
| Prevention Editorial Board | 0.379673 |
| annual screening mammogram | 0.410065 |
| National Cancer Institute | 0.431327 |
| Cancer Screening Overview | 0.412144 |
| breast cancer benefit | 0.435864 |
| breast biopsy result | 0.412172 |
| lymph vessels | 0.375923 |
| breast tumors | 0.395991 |
| breast cancer screening | 0.602061 |
| Cancer screening trials | 0.429799 |
| clinical breast exam | 0.420394 |
| breast cancer | 0.970368 |
| clinical breast | 0.421091 |
| dense breast tissue | 0.418481 |
| PDQ summary | 0.443066 |
| false-positive screening mammogram | 0.452332 |
| breast self-exams | 0.40904 |
| cancer information summaries | 0.380757 |
| comprehensive cancer information | 0.380439 |
| screening mammogram | 0.469345 |
|
CLICK HERE |
| 1669 |
National Cancer Institute |
Html |
en |
Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of childhood craniopharyngioma |
| evidence | 0.541909 |
| subtotal resection | 0.652496 |
| intensity-modulated photon therapy | 0.593647 |
| Aylwin et al. | 0.579904 |
| Merchant TE | 0.567828 |
| radiation therapy section | 0.596714 |
| PDQ cancer information | 0.54907 |
| Conventional radiation therapy | 0.591705 |
| Tumors Treatment Overview | 0.55265 |
| radiation dose | 0.548781 |
| Int J Radiat | 0.614894 |
| photon radiation therapy | 0.573627 |
| craniopharyngiomas | 0.555197 |
| cancer information summary | 0.541422 |
| Radiat Oncol Biol | 0.7952 |
| irradiated craniopharyngioma | 0.570882 |
| standard fractionated radiation | 0.630603 |
| Tan et al. | 0.575816 |
| conformal radiation treatments | 0.560832 |
| proton therapy | 0.60593 |
| tumor control | 0.588032 |
| common solid tumor | 0.565687 |
| recurrent cystic tumor | 0.550194 |
| radiation therapy | 0.986329 |
| Morisako et al. | 0.5808 |
|
| spare normal tissue | 0.555535 |
| Neurosurg Focus | 0.546254 |
| et al. | 0.839112 |
| complete resection | 0.561879 |
| magnetic resonance imaging | 0.576707 |
| newer radiation technologies | 0.623865 |
| gross-total resection | 0.656285 |
| brain tumor treatment | 0.599377 |
| residual craniopharyngioma | 0.590756 |
| pediatric craniopharyngioma | 0.701375 |
| stereotactic radiation therapy | 0.599058 |
| PUBMED Abstract | 0.577489 |
| craniopharyngioma cyst growth | 0.621968 |
| childhood craniopharyngioma | 0.72734 |
| Abstract | 0.609429 |
| external-beam radiation therapy | 0.569508 |
| pediatric brain tumors | 0.558017 |
| Sterkenburg et al. | 0.578437 |
| Oncol Biol Phys | 0.807866 |
| Neurosurg Pediatr | 0.63126 |
| recurrent craniopharyngioma | 0.572364 |
| papillary craniopharyngioma | 0.570471 |
| tumor | 0.617686 |
| craniopharyngioma | 0.809351 |
|
CLICK HERE |
| 1874 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores extragonadales de células germinativas (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores extragonadales de células germinativas. |
| germ-cell tumors | 0.383819 |
| metastatic germ | 0.316138 |
| germ-cell tumors with | 0.328427 |
| residual mass | 0.330871 |
| Nichols CR | 0.459486 |
| Greco FA | 0.321626 |
| initial salvage therapy | 0.319174 |
| largo plazo | 0.317683 |
| following systemic chemotherapy | 0.321834 |
| with germ-cell tumors | 0.328027 |
| malignant germ-cell tumors | 0.322658 |
| single-institution experience with | 0.326215 |
| unknown primary site | 0.318402 |
| germ cell tumours | 0.337125 |
| Extragonadal germ | 0.317435 |
| Cell Cancer Collaborative | 0.335481 |
| Hainsworth JD | 0.322365 |
| cell or non-germ | 0.330347 |
| Williams SD | 0.32023 |
| salvage treatment | 0.337434 |
| high-dose chemotherapy | 0.334497 |
| Instituto Nacional | 0.329901 |
| International Germ Cell | 0.371979 |
| Tumores mixtos | 0.340879 |
| Advanced poorly differentiated | 0.316704 |
|
| cell malignancy after | 0.327663 |
| primary mediastinal nonseminomatous | 0.349396 |
| unrecognized germ | 0.316359 |
| patients with | 0.426473 |
| Kramar A | 0.320119 |
| germ cell neoplasms | 0.33799 |
| disseminated germ | 0.332449 |
| Einhorn LH | 0.38746 |
| Germ Cell Consensus | 0.341019 |
| effective chemotherapy regimen | 0.321136 |
| Salvage chemotherapy | 0.319709 |
| germ cell | 0.988418 |
| PDQ Tratamiento | 0.334355 |
| extragonadal nonseminomatous germ | 0.321388 |
| Indiana University | 0.317574 |
| Clin Oncol | 0.830939 |
| as salvage treatment | 0.323614 |
| mediastinal germ-cell tumors | 0.323089 |
| mediastinal nonseminomatous germ | 0.353563 |
| postchemotherapy residual mass | 0.322319 |
| germ cell tumors | 0.75596 |
| Catalano PJ | 0.324048 |
| Oncology Group | 0.318284 |
| germ cell cancer | 0.426267 |
|
CLICK HERE |
| 1923 |
National Cancer Institute |
Html |
es |
Tratamiento del melanoma (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del melanoma. |
| almacena agua | 0.234953 |
| siguientes procedimientos | 0.33648 |
| estadio iv | 0.436307 |
| siguientes aspectos | 0.242705 |
| CTLA-4.Ampliar Inhibidor | 0.229258 |
| genes braf | 0.219515 |
| pequeña cantidad | 0.22974 |
| siguientes tipos | 0.26039 |
| estadios ia | 0.227409 |
| ganglio linfático centinela | 0.971469 |
| rayos x | 0.230817 |
| estadio ib | 0.421722 |
| estadio ia | 0.418874 |
| enlace drugs approved | 0.315654 |
| células t | 0.340582 |
| luz solar | 0.830082 |
| PD-1.Ampliar Inhibidor | 0.228522 |
| vitamina d | 0.235166 |
|
| National Cancer Institute | 0.217987 |
| lunar atÃpico | 0.239383 |
| Instituto Nacional | 0.232974 |
| estadios iia | 0.230643 |
| PDQ Tratamiento | 0.658062 |
| melanoma causa efectos | 0.315066 |
| antecedentes familiares | 0.293778 |
| cabo pruebas | 0.278327 |
| estadio iia | 0.421244 |
| estadio iic | 0.418402 |
| PDQ Exámenes | 0.269726 |
| Physician Data Query | 0.266129 |
| lápiz mide | 0.244567 |
| estadio iii | 0.594614 |
| siguientes situaciones | 0.233677 |
| panel derecho | 0.258009 |
| siguientes pruebas | 0.238893 |
| melanoma ocular uveal | 0.435674 |
|
CLICK HERE |
| 1929 |
National Cancer Institute |
Html |
es |
Tratamiento del carcinoma de sitio primario desconocido (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer metastásico que se diseminó desde un sitio primario desconocido. |
| PDQ Tratamiento | 0.503744 |
| siguientes procedimientos | 0.523984 |
| alta potencia | 0.503524 |
| siguientes elementos | 0.505673 |
| siguientes aspectos | 0.504431 |
| Physician Data Query | 0.507109 |
| coriónica humana beta | 0.506354 |
| radioterapia externa causa | 0.507986 |
| tumor primario oculto.Ampliar | 0.520296 |
| siguientes razones | 0.505928 |
| siguientes tipos | 0.504856 |
|
| vÃa oral | 0.502538 |
| rayos x | 0.503516 |
| sitio primario desconocido | 0.964151 |
| Sudores nocturnos | 0.504661 |
| cuáles pruebas | 0.503677 |
| numerosos ensayos | 0.506292 |
| National Cancer Institute | 0.501623 |
| siguientes riesgos | 0.501356 |
| células cancerosas ayuda | 0.516934 |
| Instituto Nacional | 0.503286 |
|
CLICK HERE |
| 1980 |
National Cancer Institute |
Html |
es |
Tratamiento del sarcoma de Ewing (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los tumores de la familia del sarcoma de Ewing. |
| Cirujano oncólogo | 0.631512 |
| siguientes procedimientos | 0.653106 |
| células madre | 0.978655 |
| adultos jóvenes | 0.637237 |
| faja ajustadora | 0.638641 |
| vÃa oral | 0.627826 |
| rayos x | 0.63487 |
| estudio tipos | 0.620537 |
| enlace drugs approved | 0.646857 |
| niño ayuda | 0.64117 |
| células t | 0.686984 |
| efectos tardÃos | 0.851996 |
| PDQ Efectos tardÃos | 0.679663 |
| Ewing extraóseo | 0.77445 |
| National Cancer Institute | 0.625093 |
| IRMN).Ampliar Imágenes | 0.631059 |
|
| encontrarlo.ampliar exploración | 0.638439 |
| ortopedista oncólogo | 0.633744 |
| Instituto Nacional | 0.644246 |
| PDQ Tratamiento | 0.658351 |
| determinados cambios | 0.617816 |
| Ewing causa efectos | 0.748473 |
| presente sección | 0.621848 |
| explorador tep | 0.641296 |
| nuevos tipos | 0.626452 |
| Physician Data Query | 0.690644 |
| Soft Tissue Sarcoma | 0.727359 |
| diseminó.ampliar aspiración | 0.638694 |
| quimioterapia sistémica forma | 0.678849 |
| leucemia mieloide aguda | 0.649605 |
| tumor óseo | 0.67804 |
| siguientes pruebas | 0.708113 |
|
CLICK HERE |
| 3450 |
National Cancer Institute |
Html |
en |
Planning the Transition to End-of-Life Care in Advanced Cancer (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the preparation needed by health care providers, patients, and families for the transition to end-of-life care in advanced cancer. |
| lung cancer | 0.641373 |
| Cancer patient preferences | 0.503664 |
| American Cancer Society | 0.471339 |
| palliative care cohort | 0.487911 |
| health care providers | 0.49452 |
| advance care planning | 0.617548 |
| Cancer Care Outcomes | 0.545737 |
| Care Outcomes Research | 0.519676 |
| colorectal cancer | 0.485035 |
| ill hospitalized patients | 0.478763 |
| incurable cancer patients | 0.49288 |
| breast cancer patients | 0.489402 |
| patients | 0.763742 |
| cancer patients | 0.59867 |
| elderly cancer patients | 0.49242 |
| EOL health care | 0.473964 |
| incurable cancer | 0.495495 |
| decision making | 0.513832 |
| metastatic breast cancer | 0.474641 |
| et al. | 0.585917 |
| care | 0.714724 |
| end-of-life care | 0.494853 |
| treatment | 0.487292 |
| palliative care interventions | 0.478305 |
| study | 0.52262 |
|
| Palliative care communication | 0.477608 |
| metastatic non-small-cell lung | 0.492002 |
| Palliat Support Care | 0.474344 |
| palliative care | 0.683174 |
| PUBMED Abstract | 0.539791 |
| Hosp Palliat Care | 0.499255 |
| treatment preferences | 0.470843 |
| Support Care Cancer | 0.520243 |
| advanced lung cancer | 0.489792 |
| advanced colorectal cancer | 0.478138 |
| palliative oncology care | 0.483778 |
| lung cancer patients | 0.527648 |
| early palliative care | 0.566869 |
| Intern Med | 0.533629 |
| preferences | 0.530446 |
| advanced cancer | 0.753385 |
| advance directives | 0.485421 |
| Abstract | 0.690455 |
| Clin Oncol | 0.911079 |
| Arch Intern Med | 0.488878 |
| medical care | 0.489903 |
| randomized controlled trial | 0.484267 |
| health care decisions | 0.476382 |
| cell lung cancer | 0.493742 |
|
CLICK HERE |
| 16184 |
National Cancer Institute |
Html |
es |
Manejo de costos y de información médica |
Las personas con cáncer y sus familias pueden enfrentarse a mayores retos económicos. El tratamiento de cáncer puede ser muy caro, aun cuando se tenga seguro. Aprenda cómo mantener la cuenta de tratamientos y de pruebas, de formularios y cobros, y más. |
| cuáles tratamientos | 0.380156 |
| Busque programas | 0.344502 |
| información médica clave. | 0.356222 |
| médico muestras | 0.355273 |
| expediente personal | 0.405493 |
| Health Information Management | 0.361343 |
| importante cuál sistema | 0.365142 |
|
| mayores retos | 0.375386 |
| Busque asistencia | 0.353171 |
| Busque formas | 0.327721 |
| Sociedad Americana | 0.349375 |
| busque ayuda | 0.333405 |
| seguro médico | 0.91222 |
| mano. revise cuáles | 0.413273 |
|
CLICK HERE |
| 16717 |
National Cancer Institute |
Html |
en |
Cancer Clinical Trials at the National Institutes of Health Clinical Center |
Information about cancer clinical trials at the NIH Clinical Center in Bethesda, Maryland. |
| cancer treatment | 0.534356 |
| better understanding | 0.369317 |
| clinical program | 0.414778 |
| eligibility criteria | 0.37194 |
| health insurance | 0.371915 |
| novel cancer treatment | 0.457878 |
| International patients | 0.371646 |
| health care provider | 0.502194 |
| clinical trial experience | 0.462664 |
| clinical teams | 0.407146 |
| NIH physicians | 0.420773 |
| Patients page | 0.377331 |
| NCI clinic | 0.401655 |
| open trials | 0.377021 |
| in-house cancer center | 0.477433 |
| Patient Self-Referral Form | 0.427003 |
| unique hospital | 0.366285 |
| clinical trials | 0.623234 |
| treatment services | 0.380122 |
| health care providers | 0.57596 |
| approach fosters interaction | 0.418119 |
| National Institutes | 0.375152 |
| clinical trial | 0.527278 |
| contact information | 0.370247 |
| CCR clinical trials | 0.482065 |
|
| patients | 0.409802 |
| cancer patients | 0.399962 |
| standard treatment options | 0.440025 |
| trial’s eligibility | 0.38116 |
| related research | 0.378808 |
| patient care units | 0.440886 |
| United States | 0.412623 |
| largest hospital | 0.37768 |
| cancer research | 0.528759 |
| NIH Clinical Center | 0.949828 |
| National Cancer Institute | 0.460111 |
| NCI research team | 0.453825 |
| Clinical Research Referral | 0.467688 |
| Developmental Therapeutics Clinic | 0.698646 |
| advanced cancer | 0.386466 |
| trial information | 0.38805 |
| new treatments | 0.372193 |
| NCI principal investigator | 0.437174 |
| patient treatment plans | 0.430619 |
| compassionate doctors | 0.368527 |
| care specialists | 0.389607 |
| medical care | 0.431584 |
| scientific resources | 0.368533 |
| trial summary | 0.38584 |
|
CLICK HERE |